KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 81 filers reported holding KEROS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $603,360 | -17.0% | 18,926 | +4.6% | 0.00% | – |
| Q2 2023 | $727,097 | +78.4% | 18,096 | +89.5% | 0.00% | – |
| Q1 2023 | $407,658 | +5.0% | 9,547 | +18.1% | 0.00% | – |
| Q4 2022 | $388,144 | +35.2% | 8,083 | +5.8% | 0.00% | – |
| Q3 2022 | $287,000 | +51.1% | 7,641 | +10.9% | 0.00% | – |
| Q2 2022 | $190,000 | -49.1% | 6,889 | +0.5% | 0.00% | – |
| Q1 2022 | $373,000 | +3.6% | 6,854 | +11.4% | 0.00% | – |
| Q4 2021 | $360,000 | +48.1% | 6,150 | +0.1% | 0.00% | – |
| Q3 2021 | $243,000 | +57.8% | 6,144 | +69.5% | 0.00% | – |
| Q2 2021 | $154,000 | -27.0% | 3,625 | +6.1% | 0.00% | – |
| Q1 2021 | $211,000 | -13.9% | 3,416 | -1.8% | 0.00% | – |
| Q4 2020 | $245,000 | +665.6% | 3,480 | +315.3% | 0.00% | – |
| Q3 2020 | $32,000 | -23.8% | 838 | -25.7% | 0.00% | – |
| Q2 2020 | $42,000 | – | 1,128 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |